Abstract
Mycobacterium tuberculosis infects one third of the world's population. Due to variable efficacy of the Bacille Calmette Guerin (BCG) vaccine, development of novel TB vaccines remains a priority. Here, we demonstrate the protective efficacy of a novel multivalent DNA vaccine, which contains 15 synthetic antigens targeting the Mtb ESX secretion system.
| Original language | English |
|---|---|
| Pages (from-to) | 2649-2653 |
| Number of pages | 5 |
| Journal | Human Vaccines and Immunotherapeutics |
| Volume | 12 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2 2016 |
Keywords
- DNA vaccine
- Tuberculosis
- vaccine